YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
CLINUVEL PHARMACEUTICALS (CLVLY [https://seekingalpha.com/symbol/CLVLY]) (CLVLF [https://seekingalpha.com/symbol/CLVLF]) announced that its American Depositary Shares (ADS) are expected to commence [https://seekingalpha.com/pr/20587437-cli…
The Australian stock market is experiencing a potential rebound, with shares expected to rise by over 1% following recent sell-offs, as investors anticipate the Reserve Bank of Australia's impending interest rate hike decision. In this dyn…
As the Australian market kicks off 2026, the ASX has been relatively flat with a brief pause in the Santa Rally, while IT stocks have led declines amidst broader market uncertainties. In this environment, identifying high-growth tech stock…
As the Australian market approaches the end of 2025, it appears to be in a reflective mood with a slight dip as investors engage in profit-taking before the holiday break, despite Wall Street's indices nearing record highs. In this environ…
As the Australian market experiences a tentative rise, with shares initially pointing towards gains before potential afternoon reversals, investors are closely monitoring economic indicators and broader market sentiment that could impact s…
The Australian market has been navigating a period of uncertainty, with key indices fluctuating due to geopolitical events and rising inflation, while sectors like materials have shown resilience amidst these challenges. In this environmen…
As the Australian market remains relatively stable with the ASX ending slightly in the red midweek, investors are keeping a keen eye on sectors showing resilience and potential for growth, particularly within the tech space. In this enviro…
The Australian stock market has recently experienced a notable upswing, with the ASX gaining 1.3% amid strong performances in sectors like Materials and Healthcare, driven by global economic factors such as uncertainty around a potential U…
Executive summary first biocompatible pharmaceutical formulations progress to preclinical modelsnew sustained-release drug delivery platforms for peptides, melanocortinsaim to predict drug release kinetics from new formulationsliquid formu…
The Australian market has seen mixed performances recently, with the ASX200 retreating and IT sectors showing resilience amid broader economic uncertainties, including potential US interest rate cuts and fluctuating commodity prices. In th…
* Clinuvel Pharmaceuticals press release [https://www.clinuvel.com/investor/asx-announcements/?_gl=1*17myp0j*_up*MQ..*_ga*MTM0NDQ2NDY3OS4xNzU2Mzg2MTIy*_ga_C4GX1T31ZN*czE3NTYzODYxMTkkbzEkZzEkdDE3NTYzODYxNTkkajIwJGwwJGgw#] (OTCPK:CLVLY [http…
Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025CLINUVEL’s primary listing on the ASX will remain unchanged as a result of the ADR uplis…
Key Insights Clinuvel Pharmaceuticals' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 39% of the business is held by the top 25 shareholders Recent purchases by…
Clinuvel Pharmaceuticals (ASX:CUV) has had a rough three months with its share price down 16%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes,…
As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term Clinuvel Pharmaceuticals…
Key Insights The projected fair value for Clinuvel Pharmaceuticals is AU$18.90 based on 2 Stage Free Cash Flow to Equity With AU$17.27 share price, Clinuvel Pharmaceuticals appears to be trading close to its estimated fair value Analyst pr…
It is hard to get excited after looking at Clinuvel Pharmaceuticals' (ASX:CUV) recent performance, when its stock has declined 20% over the past three months. However, a closer look at its sound financials might cause you to think again. G…
Key Insights Clinuvel Pharmaceuticals' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 25 shareholders own 45% of the company 13% of Clinuvel Pharmace…
While Clinuvel Pharmaceuticals Limited (ASX:CUV) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 12% in the last quarter. But that doesn't change the fact that th…
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investments often have little probability of ever…
Clinuvel Pharmaceuticals Limited CLINUVEL's CYACÊLLE CLINUVEL today launched CYACÊLLE, a next generation of polychromatic solar care. CYACÊLLE is designed to protect skin from a wide spectrum of damaging solar radiation under extreme condi…
UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) -- CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level 1: CLVLY) today launched CYACÊLLE, a next generat…
The latest analyst coverage could presage a bad day for Clinuvel Pharmaceuticals Limited (ASX:CUV), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Both reve…
Clinuvel Pharmaceuticals (ASX:CUV) First Half 2023 Results Key Financial Results Revenue: AU$30.7m (up 25% from 1H 2022). Net income: AU$11.4m (up 94% from 1H 2022). Profit margin: 37% (up from 24% in 1H 2022). The increase in margin was d…
Clinuvel Pharmaceuticals Limited CLINUVEL Financial Performance CLINUVEL Group financial performance for the half year ended 30 December, since first commercial sales. MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summa…
MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summary Positive Results in the Half Year to 31 December 2022 19% increase in revenues from clinical demand for SCENESSE® (afamelanotide 16mg).94% increase in NPAT; 67% incr…
Clinuvel Pharmaceuticals Limited Study in healthy volunteers shows single dose of afamelanotide reduces erythema caused by ultraviolet radiation MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical…
MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical study have shown that the drug afamelanotide can reduce critical skin damage caused by ultraviolet (UV) radiation, a leading factor in skin canc…
In this article we are going to estimate the intrinsic value of Clinuvel Pharmaceuticals Limited (ASX:CUV) by projecting its future cash flows and then discounting them to today's value. One way to achieve this is by employing the Discount…
Clinuvel Pharmaceuticals Limited Results in “children of the moon” disorder have implications for populations at highest risk of skin cancer MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic…
MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers. The trial results are the…
Most readers would already know that Clinuvel Pharmaceuticals' (ASX:CUV) stock increased by 4.1% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance.…
If you want to know who really controls Clinuvel Pharmaceuticals Limited (ASX:CUV), then you'll have to look at the makeup of its share registry. We can see that individual investors own the lion's share in the company with 54% ownership.…
The underwhelming share price performance of Clinuvel Pharmaceuticals Limited (ASX:CUV) in the past three years would have disappointed many shareholders. What is concerning is that despite positive EPS growth, the share price has not trac…
It's been a soft week for Clinuvel Pharmaceuticals Limited (ASX:CUV) shares, which are down 14%. But that scarcely detracts from the really solid long term returns generated by the company over five years. We think most investors would be…
Does the August share price for Clinuvel Pharmaceuticals Limited (ASX:CUV) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to today's value.…